Surface modification with cholesteryl acetyl carnitine, a novel cationic agent, elevates cancer cell uptake of the PEGylated liposomes

• Published in: International journal of pharmaceutics 2021-11, Vol.609, p.121148-121148, Article 121148
• Main Authors: Zahednezhad, Fahimeh, Shahbazi Mojarrad, Javid, Zakeri-Milani, Parvin, Baradaran, Behzad, Mahmoudian, Mohammad, Sarfraz, Muhammad, Valizadeh, Hadi
• Format: Article
• Language: English
• Subjects: Acetyl carnitine; Acetylcarnitine; Cancer therapy; Cations; Cell uptake; Cholesterol; Liposome surface modification; Liposomes; Molecular Docking Simulation; Neoplasms - drug therapy; Particle Size; Polyethylene Glycols; Synthesis
• ISSN: 0378-5173; 1873-3476
• DOI: 10.1016/j.ijpharm.2021.121148

[Display omitted] •A novel cationic agent named cholesteryl acetyl carnitine (CAC) was synthesized.•CAC effectively interacts with CAT, CPT, OCTN1 and OCTN2.•CAC/PEG modified and CAC + PEG modified liposomes were prepared and characterized.•Co-modified liposomes with PEG and CAC demonstrated higher uptake by A549 cells.•CAC modified liposomes showed the lowest IC50 in A549 cells. The present study aimed to synthesize cholesteryl acetyl carnitine (CAC), and surface modify the PEGylated liposomes with the intention of enhanced cancer cell uptake. For this, CAC synthesis was performed in amine-free esterification conditions and then four liposomal formulations of unmodified, CAC/PEG, and CAC + PEG-modified were prepared by ethanol injection method. Cytotoxicity of the liposomes was investigated in A549 cells, followed by cellular uptake assessments of coumarin 6 (C6)-loaded liposomes. The results of ATR-FTIR, 1HNMR, and 13CNMR demonstrated successful formation of CAC. A molecular docking study showed efficient binding affinities rather than carnitine to the active site of four carnitine transporters. Liposomal formulations possessed spherical morphology with a mean particle size range of 112–138 nm, narrow size distribution, and negative surface charge. All formulations had low cytotoxicity at 0.5 mg/ml, but high cytotoxicity at around 2.5 mg/ml. The lowest IC50 was obtained for CAC modified liposomes. CAC + PEG-modified liposomes had the highest cellular uptake. In conclusion, CAC + PEG modification of liposomes is an effective approach for increasing A549 cellular uptake, with low cytotoxicity at commonly applied liposome concentrations. The elevated uptake may be due to the involvement of the organic cation transporter, cationic structure, and the metabolic preference of CAC in cancer cells.